Le Lézard
Classified in: Business
Subject: ATY

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI


NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

The investigation concerns whether Karyopharm and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On February 22, 2019, in advance of a U.S. Food and Drug Administration ("FDA") advisory committee meeting to review Karyopharm's New Drug Application ("NDA") for selinexor and assess the drug's risks and benefits, the FDA released a briefing document expressing serious concerns about the safety and efficacy of selinexor (the "FDA Report").  Significantly, the FDA Report revealed that, contrary to Karyopharm's assurances, the Company's previously canceled Phase 2 SOPRA trial had resulted in "worse overall survival" for acute myeloid leukemia ("AML") patients treated with selinexor, which "highlight[ed] the toxicity of this drug."  The FDA also determined that the toxicity observed with selinexor in AML patients in the SOPRA study was "similar" to that observed in multiple myeloma patients in the Phase 2b STORM study.  The FDA unambiguously concluded that "[t]reatment with selinexor is associated with significant toxicity" and has "limited efficacy."  On this news, Karyopharm's stock price fell $3.90 per share, or 43.48%, to close at $5.07 per share on February 22, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

 

SOURCE Pomerantz LLP


These press releases may also interest you

at 10:54
LatentView Analytics Limited (BSE: 543398, NSE: LATENTVIEW), a global digital analytics consulting and solutions firm, today announced the Board approval on the acquisition of Decision Point, for acquisition of 70% of outstanding equity capital for a...

at 10:49
United Community has once again topped the J.D. Power 2024 U.S. Retail Banking Satisfaction Study, ranking highest in Customer Satisfaction with Consumer Banking in the Southeast. This is the tenth time United Community has won the prestigious award....

at 10:49
Colony Roofers (CCC1335429), renowned for its premier quality roofing services across the southeast, announces the opening of a new office in Tampa, Florida, solidifying its commitment to serving Florida residents and businesses. Strategically...

at 10:49
A new measure to protect Florida consumers against dishonest towers was signed into law recently by Governor Ron DeSantis (R-FL). The legislation (HB 179), which was strongly supported by the National Insurance Crime Bureau (NICB), will provide...

at 10:49
The Prime Minister, Justin Trudeau, today announced that the Prime Minister of France, Gabriel Attal, will travel to Canada from April 10 to 12, 2024. Canada and France enjoy a strong relationship rooted in close co-operation and shared history,...

at 10:46
FullCare Medical has launched a new medical garment production facility in Tatu City, the 5,000-acre mixed-use Special Economic Zone (SEZ) in Kenya....



News published on and distributed by: